


































Pharmaceuticals – Pipeline Overview¹ (as of April 30, 2024)

Phase I	Phase II	Phase III
HER2/mEGFR Inhibitor (BAY 2927088)  ●	Congestive Heart Failure rAAV Gene Therapy (AB-1002)  ● # Congestive Heart Failure (GenePHIT)	Darolutamide (AR Inhibitor)  ○
DGKzeta Inhibitor (BAY 2965501)  ●	Anti-a2AP (BAY 3018250)  ● # Acute Ischemic Stroke; Pulmonary Embolism (SIRIUS)	Finerenone (MR Antagonist)  ○
CCR8 Ab (BAY 3375968)  ●	Runcaciguat (sGC Activator) (BAY 1101042)  ● # Non-prolif. Diabetic Retinopathy (NPDR) (NEON-NPDR)	Vericiguat (sGC Stimulator)  ○
VVD KEAP1 Act (VVD-130037 aka NRF2 Inh, BAY 3605349)  ●		Asundexian (FXIa Inhibitor)  ●
DGKalpha Inh (BAY 2862789)  ●		Elinzanetant (Neurokinin-1,3 Rec Antagonist)  ●
225Ac-Pelgifatamab (BAY 3546828)  ●		Aflibercept 8mg (VEGF Inhibitor)  ○
VVD STAT3 Inhibitor (VVD-130850, BAY 3630914)  ●		Gadoquatrane (High Relaxivity Contrast Agent)  ●
225Ac-PSMA-Trillium (BAY 3563254)  ●		
sGC Activator Oral (BAY 3283142)  ●		
SEMA 3a (BAY 3401016)  ●		
Anti-coagulant (BAY 3389934)  ●		
Bemdaneprocel (Parkinson's Disease Cell Therapy) (BRT-DA01)  ●		
Parkinson's Disease rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-PD)  ●		
Multiple System Atrophy rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-MSA)  ●		
Pompe Disease rAAV Gene Therapy (ACTUS-101)  ●		
Huntington's Disease rAAV Gene Therapy (AB-1001 aka BV-101)  ●		
LGMD2I/R9 rAAV Gene Therapy (AB-1003 aka LION-101)  ●		
GPR84 Antagonist (BAY 3178275)  ●		
BAY 2701250  ●		
		Submissions
		Aflibercept 8mg (VEGF-Inhibitor)  ○ # CN: Neovasc. Age-rel. Macular Degen. (nAMD)
		Acoramidis⁴ (TTR-Stabilizer)  ● # EU: Transthyretin Amyloid Cardiomyopathy

- Oncology
- Cardiovascular+³
- Neurology & Rare Diseases
- Immunology
- Others

- New molecular entity
- Life cycle management



¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit
² Conducted by Merck & Co ³ Including Precision Cardiovascular, Nephrology & Acute Care
⁴ Exclusive commercialization rights acquired for EU markets; pending marketing authorization approval. Submission to EMA under responsibility of BridgeBio